Interview with CEO Tony Paré and CFO Niel Goldman - Full Year 2022 report
Interview with CEO Tony Paré and CFO Niel Goldman - Full Year 2022 report
Bioporto received an AI letter from FDA, which is a standard procedure and nothing to worry about. CEO Tony Paré seems very confident about the process and expect to deliver on the deadline end June 2023. While they wait for the outcome from FDA, they turn their focus on Europe where they have a CE-approval of NGAL.
CFO Niel Goldman gave a detailed explanation of the 2022 numbers. They expect better sales and lower ebitda loss for 2023.
Please listen here: https://www.inderes.dk/videos/bioporto-presentation-of-annual-report-2022
Disclaimer:
HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 3:00 PM 03-31-2023.
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page